CSF3 and AL amyloidosis: On the other hand, administrating filanesib (ARRY520) as combination therapy resulted in more promising results in phase I/II for multiple myeloma when used as combination with pomalidomide (anti-angiogenic), Bortezomib (proteasome inhibitor), Dexamethasone and the granulocyte colony-stimulating factor (G-CSF) filgrastim (please refer to Table 2 for the clinical trial results of filanesib in monotherapy combination therapy) [46,47].